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Fifty-four type 2 diabetic patients with neuroischemic foot ulcers were randomised to treatment with 5000IU of dalteparin,
(n = 28), or physiological saline, (n = 26), once daily until ulcer healing or for a maximum of 6months. Thirty-three patients
had normo-, 15 micro-, and 6 macroalbuminuria. The urinary levels of IgM and IgG2 were elevated in 47 and 50 patients,
respectively. Elevated urinarylevelsofIgMandIgG2 indicatedecreased glomerularsizeselectivity. UrineIgM levelswere associated
with IGF-1/IGFBP-1 and IGFBP-1 levels. Dalteparin treatment increased urinary levels of glycosaminoglycans (P<0.001) and
serum IGFBP-1 (P<0.05) while no signiﬁcant eﬀects were seen in any of the other studied parameters. In conclusion, dalteparin
therapy in patients with type 2 diabetes had no eﬀects on urinary levels of albumin, IgM, or IgG2 despite signiﬁcantly increased
glycosaminoglycans in urine. Elevated urinary levels of IgM and IgG2 might be more sensitive markers of renal disease than
albuminuria in patients with type 2 diabetes and antihypertensive therapy.
1.Introduction
Albuminuria is a marker of diabetic nephropathy and a
strong predictor of widespread vascular damage [1]. The
Steno hypothesis held that genetically based disturbances
in the production or sulphation of heparan sulphate (HS)
lead to a reduction of sulphated and negatively charged HS
glycosaminoglycan (GAG) side chains. Negatively charged
HS GAG side chains are normally found in the extracellular
matrix and vascular basement membranes. High blood
glucose levels lead to lower activity of the enzymes involved
in GAG metabolism and sulphation of HS [2]. A reduction
of negatively charged HS GAG may induce an increased
transvascular permeability ofnegatively charged plasma pro-
teins, which promotes vascular and glomerular changes [1,
3–5]. Positive eﬀects of heparin on diabetic nephropathy
have been shown in experimental studies [6–8]. In humans
with diabetes, several studies have shown a reduction of uri-
nary albumin excretion during treatment with unfractioned
heparin, low-molecular-weight heparins (LMWH), or oral
treatment with sulodexide, suggesting that these compounds
can improve GAG metabolism and sulphation of HS [3].
Thus,inpatientswithtype1diabetes,treatmentwithunfrac-
tionated heparin, sulodexide or LMWH decreased the albu-
min excretion rate [9, 10], whereas in type 2 diabetes, the
eﬀect on albuminuria seems less consistent [3]. In a study by2 Biochemistry Research International
Nielsen et al., three weeks of daily injections of the LMWH
tinzaparin had no eﬀect on albuminuria in patients with
type 2 diabetes [11]. We have earlier reported an improved
outcome of chronic neuroischemic foot ulcers in patients
with diabetes during long-term treatment with dalteparin
[12]. The beneﬁcial eﬀects of dalteparin on ulcer outcome
involved an inhibitory eﬀect on thrombin generation and
improved haemostatic and microvascular functions [13].
Thedescribed eﬀectsofdalteparinmaybe beneﬁcialnotonly
for outcome of neuroischemic diabetic foot ulcers but also
for other complications, such as diabetic nephropathy. Thus,
the aim of this ancillary study was to investigate the eﬀect
of treatment with the LMWH dalteparin on proteinuria in
patientswithdiabetesandseverevascularcomplications.The
selectivity of the glomerular ﬁlter was studied by analyzing
the urinary excretion of molecules of diﬀerent size and
charges [14–17], that is, IgM was analysed for determination
of the size, and IgG2 and IgG4 for determination of the neu-
traland negative chargesoftheglomerularﬁlter, respectively.
The glomerular mesangial matrix turnover was assessed by
measuring the urinary excretion of cytokine transforming
growth factor beta 1 (TGFβ1) [18]. Furthermore, we ana-
lyzed insulin-like growth factor 1 (IGF-1) and IGF-binding
protein 1 (IGFBP-1) since the IGFBP-1 [19]a n dI G F 1h a v e
been shown to be associated with diabetes nephropathy
independent of the degree of albumin [20]. It has been
speculated that low IGF-1 activity may induce apoptosis or
loss of podocytes and thus lead to glomerulosclerosis [21].
2.Subjectsand Methods
2.1.Subjects. Ofthepreviouslydescribed87diabeticpatients
[12] with peripheral arterial occlusive disease (PAOD) and
chronic foot ulcer,54 type2 diabetic patientswho completed
the urine collections were included in the present study. All
patients were treated with 75mg aspirin once daily since at
least four weeks before randomization and throughout the
study period.
2.2. Methods. Prospective, double-blind, and placebo-con-
trolled multicenter study to evaluate the eﬀects of dalteparin
(Fragmin,Pﬁzer) primarilyonhealing ofneuroischemicfoot
ulcers [12] and secondarily on haemostatic and microvascu-
lar functions [13], and renal excretion of proteins. The pa-
tients were randomized to treatment with 0.2mL daily sub-
cutaneous injections of dalteparin (25000U/mL) or physio-
logical saline until ulcer healing or for a maximum of six
months.
Timed urine collections from three consecutive nights
before and at the end of treatment were stored at −20◦Ca n d
analyzed at the Renal Laboratory, Lund. Microalbuminuria
was deﬁned as a mean value of the urine collections of 20 to
200μg/min or u-albumin/creatinine ratio of3–30mg/mmol.
An excretion below these levels was deﬁned as normo- and
an excretion above as macroalbuminuria.
Urine albumin [22], total GAG [23], IgM [24], IgG2,a n d
IgG4 [25] were analyzed as previously described. Biologically
active TGFβ1 was analyzed with a commercially available
assay (Emax Immunoassay System, Promega Corp., Madi-
son, WI, USA).U-creatinine was analyzed with an enzymatic
method (EKTACHEM, Clinical Chemistry Slide, Johnson &
Johnson Clinical Diagnostics, Rochester, NY, USA). HbA1c
was analyzed by an immunoturbidimetric method (UNI-
MATE 3 HbA1c, Roche Diagnostics). HsCRP and S-AA were
measured using particle-enhanced immunonephelometric
methods (BN, Dade Behring). IGF-I [26]a n dI G F B P - 1[ 27]
were determined in serum by radioimmunoassays (RIAs).
2.3. Statistical Methods. Dataare shown as mean and SDand
skewed variables as median (minimum and maximum val-
ues). For diﬀerences within subjects we used Friedman’s test,
with Wilcoxon signed-rank test as post hoc test. The chi-
square test was used to compare diﬀerences in the distri-
bution of categorical variables. For testing of diﬀerences be-
tween subject groups, the Mann-Whitney U test was used. P
values below 0.05 were considered signiﬁcant (2-tailed). The
statistical program SPSS was used.
2.4.Ethical Considerations. The study protocolwas approved
by the local ethics committee of each centre and the Swedish
Medical Products Agency. Written informed consent was
obtained from all patients.
3.Results
3.1. Patient Characteristics. Fifty-four patients with type 2
diabetes were able to leave timed urine collections from
three consecutive nights before and at the end of treatment
period. All patients had PAOD, peripheral neuropathy, and
chronic footulcers.Sevenpatientsinthedalteparinand 10in
the placebo group had suﬀered from myocardial infarction,
and two patients in the placebo group had undergone leg
amputation. Except for more ex-smokers in the placebo
group, the baseline patient characteristics were not diﬀerent
betweenthetwogroups(Table 1).LevelsofHbA1c atbaseline
(Table 1) and at the end of treatment period (dalteparin: 7.0
(4.9–10.8)%; placebo: 6.3 (4.6–8.7)%) were not signiﬁcantly
diﬀerent between the groups. Ten patients in the dalteparin
groupand11intheplacebogrouphadmicro-ormacroalbu-
minuria (Table 1). Thirty-six patients, including 23 patients
with normoalbuminuria, were on antihypertensive treat-
ment (Table 1).
3.2. Treatment Period. The treatment period with dalteparin
was not signiﬁcantly diﬀerent from the treatment period in
the placebo group. It lasted for median 26 and range 8 to 26
weeks.
3.3. Renal Parameters. At baseline, 33 patients had normo-
, 15 micro-, and 6 macroalbuminuria. Thirty-six patients,
including 23 patients with normoalbuminuria, were on anti-
hypertensive treatment (Table 1). Ten patients in the dal-
teparin group and 11 in the placebo group had micro- or
macroalbuminuria (Table 1). Forty-seven patients showed
elevated urinary levels of IgM (Figure 1), while 50 patients
hadelevatedurinary levelsofIgG2,bothindicatingdecreasedBiochemistry Research International 3
Table 1: Baseline characteristics of 54 patients randomized to dalteparin or placebo.
All Dalteparin Placebo
N = 54 N = 28 N = 26
Age (years) 75 (54–90) 73 (57–86) 75 (54–90)
Gender (male/female) 37/17 17/11 20/6
Smoker/ex-smoker/nonsmoker(n) 9/14/31 4/3/21∗ 5/11/10
HbA1c (%) 6.7 (5.0–11.0) 6.9 (5.1–11) 6.9 (5.0–9.6)
Diabetes duration (years) 17 ± 91 7 ± 10 16 ± 8
Tablets/insulin/tablets + insulin/diet (n) 10/31/8/5 4/18/3/3 6/13/5/2
Antihypertensive treatment (n)
(ACE/β/Ca/diuretic/other) 10/13/5/22/4 5/6/3/14/0 5/7/2/8/4
Systolic blood pressure (mmHg) 158 ± 22 160 ± 22 155 ± 22
Diastolic blood pressure (mmHg) 80 ± 11 78 ± 98 2 ± 12
P-Creatinine (μmol/L) 83 (53–160) 83 (57–130) 84 (53–160)





Baseline (n) 33/15/6 18/8/2 15/7/4
At endpoint (n) 35/12/7 18/7/3 17/5/4



























Figure 1: Box-plot of levels of IgM in control subjects compared
withpatients withnormo-andmicro-ormacroalbuminuriaat bas-
eline (P<0.001). Normo- versus micro- or macroalbuminuria
(P = 0.05).
glomerular size selectivity. Twelve patients had a ratio of
IgG2/IgG4 less than 1 indicating decreased charge selectivity,
while 8 patients had urine levels of GAG less than or equal to
2mg/mmol.
Urinary GAG increased from 2.43 (0–8.65) mg/mmol
at baseline to 3.40 (1.25–8.0) mg/mmol during dalteparin
therapy (P<0.001), while GAG levels were not signif-
icantly changed in the placebo group (baseline: 2.53 (0–
8.99) mg/mmol). All other urinary parameters, including
glomerular ﬁltration rate (GFR), were not signiﬁcantly dif-
ferent between dalteparin- and placebo-treated patients at
baseline or at the end of treatment (Tables 1 and 2;d a t aa t
endoftreatment notshown). Baseline levelsofsystolic blood
pressure, HbA1c, S-creatinine, S-HsCRP, S-AA, S-IGF, S-
IGFBP-1, U-GAG, and U-IgG2/IgG4 were not signiﬁcantly
diﬀerent between patients with normo- and micro- or
macroalbuminuria (Table 2),andnoassociations werefound
between urinary GAG, HbA1c, and blood pressure levels
and the urinary parameters. Urine levels of IgG2 and IgG4
were higher in patients with micro- or macroalbuminuria
than in those with normoalbuminuria (P<0.05) (Table 2).
The dalteparin-induced increase in urinary GAG was inde-
pendent of the degree of albuminuria, and no gender dif-
ferences were found (data not shown). No signiﬁcant eﬀects
of dalteparin treatment were seen on the urinary excretion
of proteins in either patients with normoalbuminuria, or in
patients with micro- or macroalbuminuria (Tables 3 and 4).
3.4. Comparisons with Data from Control Subjects. In com-
parison with control subjects [28], the urinary levels of IgG2
werehigherinthepatientswithmicro-ormacroalbuminuria
while normal in those with normoalbuminuria. Levels of
IgG4 were normal, while IgG2/IgG4 ratios, and IgM and
TGFβ1-values [18] were increased irrespective of the level of
albuminuria (for reference values, see Table 2).
3.5. Inﬂammatory Parameters, IGF-1 and IGFBP-1. The lev-
els of hsCRP, SAA, S-IGF-1, and S-IGFBP-1 were similar in
the dalteparin and placebo groups at baseline and during the
treatment period (data not shown), except for S-IGFBP-1
whichincreasedinpatientswithmicro-macroalbuminuria in
comparison with placebo-treated patients (Tables 3 and 4).
No associations were found with any of the urinary parame-
ters or HbA1c levels. S-IGF-1 was negatively associated with
systolic BP at entry (r =− 0.304, P = 0.048, n = 43).
SAA and hsCRP were negatively associated with systolic BP
at endpoint (r =− 0.294, P = 0.038, n = 50 and r =− 0.292,4 Biochemistry Research International
Table 2: Baseline values in patients grouped with normo- or micro- and macroalbuminuria.
Normoalbuminuria Micro- and macroalbuminuria
N = 33 N = 21
Age (years) 74 (54–90) 75 (61–86)
Diabetes duration (years) 15 ± 91 9 ± 8
Gender (male/female) 21/12 16/5
Systolic blood pressure (mmHg) 150 (115–210) 160 (135–215)
Diastolic blood pressure (mmHg) 80 (60–100) 85 (60–105)
S-HbA1c (%) 6.5 (5.0–9.9) 6.9 (5.1–11.0)
S-Creatinine (μmol/L) 81 (53–160) 85 (65–128)
S-Hs CRP (mg/L) 9.4 (0.9–118) 2.7 (0.3–78.2)
S-AA (mg/L) 5.5 (1.2–415) 5.1 (1.7–127)
S-IGF-1 (μg/L) 134 (47–384) 115 (49–269)
S-IGFBP-1 (μg/L) 41 (15–310) 60 (8–313)
U-Glycosaminoglycan (mg/mmol)a 2.7 (0–8.7) 2.6 (0–11.1)
U-IgG2 (mg/mmol)b 0.18 (0–8.1) 0.85 (0–99)∗
U-IgG4 (mg/mmol)c 0.06 (0–7.7) 0.27 (0–28.7)∗
U-IgG2/IgG
d
4 3.1 (0.04–31.0) 3.3 (0.76–10.5)
U-IgM (mg/mmol)e 0.02 (0–0.06) 0.03 (0–0.13)
U-TGFβ1 (ng/mmol) 3.2 (1.1–379) 4.5 (1.4–16.5)
∗P<0.05 versus normoalbuminuria. Data are given as median and range (min-max). Urine data are the ratio between urine protein and urine creatinine.
aReference values for U-GAG: 2.9 (2.0–4.4) mg/mmol [25]; bU-IgG2:0 . 1 9± 0.14mg/mmol; cU-IgG4:0 . 3 5± 0.25mg/mmol; dU-IgG2/IgG4:2 . 3± 0.7; eU-
IgM: 0.002 ± 0.001mg/mmol [28]. IGFBP-1 (15–45) [29, 30].
Table 3: Diabetic patients with normoalbuminuria: eﬀects of treatment on urinary indices.
Dalteparin Placebo
Baseline At endpoint Baseline At endpoint
n = 18 n = 18 n = 15 n = 15
U-Albumin (mg/mmol) 0.81 (0.07–2.39) 0.77 (0.06–4.97) 0.81 (0.13–4.09) 0.80 (0.19–6.73)
U-IgG2 (mg/mmol) 0.19 (0–8.14) 0.14 (0–7.79) 0.18 (0.06–2.64) 0.16 (0.01–3.79)
U-IgG4 (mg/mmol) 0.05 (0–7.68) 0.04 (0–1.08) 0.07 (0.02–2.51) 0.06 (0.02–4.63)
U-IgG2/u-IgG4 3.49 (0.04–31) 2.20 (0.37–44.59) 2.38 (0.41–8.58) 2.63 (0.54–18.7)
U-GAG (mg/mmol) 2.43 (0.86–8.65) 2.85 (1.32–8)∗# 3.32 (0–6.45) 2.53 (0.93–8.99)
U-IgM (mg/mmol) 0.02 (0–0.06) 0.02 (0–0.05) 0.02 (0–0.05) 0.02 (0–0.05)
TGF-β1 (mg/mmol) 3.2 (1.1–379) 5.17 (1.47–21.3) 3.4 (1.4–24.6) 3.32 (1.7–28.9)
GFR (mL/min) 70 (34–190) 65 (33–163) 99 (17–218) 86 (20–334)
(n = 14) (n = 13) (n = 12) (n = 12)
IGFBP-1 (μg/L) 42 (21–310) 49 (27–315) 38 (15–98) 53 (15–97)
Dataaregiven asthemedian(withminimumandmaximumvaluesinparentheses) oftheratiobetweenurinary concentrationsof substanceandu-creatinine.
∗P<0.05 versus placebo; #P<0.05 versus baseline. GFR: glomerular ﬁltration rate: creatinine clearance.
P = 0.036,n = 52;resp.).Nodiﬀerenceswerefound between
normo- and micro- or macroalbuminuric patients (Table 2).
However, urine IgM/creatinine ratio was correlated to IGF1/
IGFBP1 (r =− 0.36, P = 0.008, n = 54) and IGFBP1 (r =
0.34, P = 0.013, n = 54).
4.Discussion
Theresultsofthepresentstudyshowthatsixmonthsoftreat-
ment with the LMWH dalteparin had no eﬀect on glomeru-
lar function, inﬂammatory parameters, or urinary levels of
proteins despite an increased urinary excretion of GAG. Our
results extend the ﬁndings of an earlier study showing that
three weeks of LMWH treatment had no eﬀect on albumin-
uria in patients with type 2 diabetes [11]. These ﬁndings
are in contrast to the eﬀect seen in type 1 diabetic patients
showing a reduced albuminuria during one-to-three month
treatment with either unfractionated heparin or LMWH
[9, 10]. The reason for this discrepancy in eﬀects of heparins
on urinary excretion of proteins between patients with type
1 and type 2 diabetes is unclear and cannot be explained
by the present study. However, the structure of the heparinBiochemistry Research International 5
Table 4: Diabetic patients with micro- or macroalbuminuria: eﬀects of treatment on urinary indices.
Dalteparin Placebo
Baseline At end point Baseline At end point
n = 10 n = 10 n = 11 n = 11
U-Albumin (mg/mmol) 8.5 (0.9–435) 11.3 (1.5–311) 23.2 (2.1–187) 7.9 (0.9–273)
(n = 10)
U-IgG2 (mg/mmol) 0.46 (0–20.7) 0.83 (0.13–35.1) 2.99 (0.02–99.4) 2.60 (0–70.0)
U-IgG4 (mg/mmol) 0.21 (0–3.94) 1.02 (0.04–7.16) 0.50 (0.03–28.7) 0.15 (0–53.7)
(n = 10)
U-IgG2/u-IgG4 1.88 (1–10.5) 3.05 (0.33–9.16) 5.57 (0.8–9.7) 4.47 (0.35–24.1)
U-GAG (mg/mmol) 2.31 (0–4.52) 3.97 (1.25–6.1)∗## 2.70 (0–11.1) 2.49 (0–5.19)
(n = 10)
U-IgM (mg/mmol) 0.03 (0–0.05) 0.03 (0.01–0.12) 0.03 (0–0.13) 0.02 (0–0.14)
TGF-β1 (mg/mmol) 4.44 (1.4–15.9) 4.09 (2.14–14.12) 4.5 (1.8–16.5) 3.5 (1.19–22.44)
(n = 10)








IGFBP-1 (μg/L) 66 (8–313) 105 (23–219)∗
(n = 9) 60 (20–130) 46 (10–161)
Dataaregiven asthemedian(withminimumandmaximumvaluesinparentheses) oftheratiobetweenurinary concentrationsof substanceandu-creatinine.
∗P<0.05 versus placebo; ##P<0.01 versus baseline. GFR: glomerular ﬁltration rate: creatinine clearance.
molecule might be of importance since mixed compositions
of sulphated GAG and heparan sulphate, for example, dana-
paroid [31], seemed to be more eﬀective in type 2 diabetic
patients. Another compound sulodexide which is a mixture
of glucuronyl glycos aminoglycan and dermatan sulphate
in an early study seemed to be eﬀective [32], while a later
double-blind randomized study showed that the drug was
unable to decrease urine albumin excretion in patients with
type 2 diabetic nephropathy and microalbuminuria [33].
The levels of total urinary GAG increased during treat-
ment with dalteparin, which may be due to restitution of
glomerular GAG or simply by an increased urinary excre-
tion of dalteparin [34]. The low-molecular-weight heparin
dalteparin is composed of strongly acidic sulphated polysac-
charide chains with an average molecular weight of 5000
and about 90% of the material within the range 2000–9000.
An earlier study by our group showed normal excretion of
GAG in normoalbuminuric type 1 diabetic patients, while
the levels were decreased in micro- and macroalbuminuric
patients [25]. In contrast, the present study showed no
signiﬁcant diﬀerences in the levels of GAG in patients with
normal or increased urinary excretion of albumin.
Normally, the urinary levels of IgG2,I g G 4,a n dI g Ma r e
undetectable. In the present study, more patients had in-
creased levels of urinary IgG2, IgG2/IgG4 ratio, or IgM than
patients who had micro- or macroalbuminuria. The loss
of negative charges of the glomerular capillary wall causes
the “eﬀective” small pore radius vis-` a-vis negatively charged
macromolecules to increase to ∼4.5nm, which allows the
passage of albumin. Larger proteins, such as IgG (mol radius
5.5nm) or IgM (mol radius 12nm), are still unable to pass
across this pathway. IgG passes the glomerularcapillary walls
through the large pores, while IgM can permeate the glom-
erular capillary wall solely through the shunts [28]. Thus,
increasedtransportofIgGindicatesincreaseddensityoflarge
pores, while increased concentration of urine IgM indicates
increased density of shunts in the glomerular capillary wall
[28]. In the present study, 47 patients had detectable levels
of IgM, while only 21 patients had albuminuria; thus, renal
disease was found in patients not detected by analysis for
urine albumin. Since peripheral arterial occlusive disease
is a marker of widespread vascular disease, one could
expect that more patients in the present study would have
had albuminuria. One reason for the low number may be
antihypertensive medication, which was common in the
present study. Thus, albuminuria may be a less sensitive
parameter for evaluating nephropathy in patients on anti-
hypertensive treatment. LMWH had no eﬀect on the other
urinary parameters studied, that is, IgG2/IgG4,I g G 2 or IgM.
In recent years new technologies of genomic analysis and
proteomic approaches have detected several new markers for
renal disease like neutrophil gelatinase-associated lipocalin
(NGAL), kidney injury molecule-1 (KIM-1), and podocin
[35–37]. However, the substances have not been proved to
be of signiﬁcant prognostic value and thus the ﬁndings have
not resulted in improvement of the management of diabetic
nephropathy [38, 39].
We have previously found higher renal excretion of IgM,
IgG2,a n dI g G 2/IgG4 in type2than in type1diabetic patients
with overt nephropathy despite similar degree of albumin-
uria [28]. Thus, proteinuria in type 2 diabetic patients may
be caused by an alteration of the size selective properties of
the glomerular capillary wall, including the occurrence of
nondiscriminatory “shunt pathways,” rather than by charge
selectivity [15]. We have previously found increased excre-
tion of IgM to be a poor prognostic factor [40]. The IGFBP-
1 gene has been suspected to be protective for nephropa-
thy [19], possibly through altered IGFBP-1 binding to IGF-16 Biochemistry Research International
with local eﬀect in the kidney. In the present study in
patients with vascular disease we found increased excretion
of IgM, and thus these patients may be at increased risk. We
furthermore found a positive association between IGFBP-
1 and excretion of IgM indicating that high IGFBP-1 may
be associated with glomerular damage. Thus, we were able
to conﬁrm decreased levels of IGF-1 and increased levels of
IGFBP-1 in type 2 diabetes patients with nephropathy [20].
Furthermore,IGFBP-1increasedtosigniﬁcantlyhigherlevels
in patients treated with dalteparin than in placebo-treated
ones. The reason for these increased levels is not known
but may be due to reduced proteolysis of IGFBP-1. In line
with a study by Sharma et al. [18], the present study showed
increased urinary levels of TGFβ1 in patients with type 2
diabetes. However, the levels of TGFβ1w e r ea l s ou n a ﬀected
by dalteparin treatment.
In conclusion, the present study showed no eﬀects of
dalteparin on the glomerular ﬁlter despite increased S-
IGFBP-1levelsandurinary levelsofGAG.Thus,thestudyin-
dicates that proteinuria in type 2 diabetic patients may be
caused by an alteration of the size-selective properties of the
glomerular capillary wall. IgM and IgG2 seem to be better
markers than albuminuria for severe vascular disease.
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